Authors

Latest:

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Natasha B Leighl, MD, BSc, MMSc

Latest:

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Naomi Adjei, MD, MPH, MSEd

Latest:

Dr Adjei on the Rationale for Opportunistic Salpingectomy for Ovarian Cancer Prevention

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Chetasi Talati, MD

Latest:

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Manmeet S. Ahluwalia, MD, MBA, FASCO

Manmeet S. Ahluwalia, MD, MBA, FASCO, is the deputy pirector, chief scientific officer, chief of medical oncology, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute, which is part of Baptist Health South Florida.

Latest:

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

John Michael "JM" Bryant, MD

Latest:

Dr Bryant on the Influence of Germline DNA Repair Mutations on Therapeutic Development in PDAC

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

David D'Ambrosio, MD

Latest:

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Bernard Doger de Spéville, MD, PhD

Latest:

Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCC

Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.

Jonathan M. Gerber, MD

Jonathan M. Gerber, MD, is a member of the faculty in the Department of Medicine at New York University (NYU) Grossman School of Medicine; as well as the chief clinical officer of the NYU Perlmutter Cancer Center.

Latest:

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Surbhi Sidana, MD

Latest:

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

Experts discuss strategies for managing and mitigating early vs late chimeric antigen receptor (CAR) T-cell therapy–related toxicities, offering advice to practitioners, and share additional clinical pearls on improving the overall CAR T process in academic and community settings.

Nikolai Podoltsev, MD, PhD

Nikolai Podoltsev, MD, PhD, is an associate professor of internal medicine (hematology); Duffy Firm Chief for Education, Department of Internal Medicine; associate director, Hematology/Oncology Fellowship Program, Department of Internal Medicine; clinical director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology, Yale Cancer Center.

Latest:

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Michelle Chi, MD

Latest:

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Gregory Peter Kalemkerian, MD

Latest:

Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC

Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.

Nelli Bejanyan, MD

Latest:

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Kersti Oselin, MD, PhD

Latest:

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Lindsay L. Kroener, MD

Latest:

Dr. Kroener on Utilizing Embryo Cryopreservation in Breast Cancer

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

Payal D. Shah

Latest:

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Mark Pegram, MD, Stanford Women's Cancer Center

Latest:

Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Arvind N. Dasari, MD, MS

Latest:

Dr Dasari on the Evolving Treatment Paradigm in mCRC

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Nilo Azad, MD

Latest:

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.